Shares of Sellas Life Sciences Group Inc. gained 156% on Tuesday, November 17, after the drug developer reported positive late-stage trial results for an experimental cancer vaccine that could be used to treat an aggressive form of blood cancer.
In its report, the New York-based Sellas said its vaccine, galinpepimut-S, reduced the risk of death by 41% compared with the best available treatment for patients with acute myeloid leukaemia. Patients who received the vaccine had a median overall survival of 24 months, compared to less than 15 months for those receiving other treatments.
The 156% surge was the biggest single-day gain since 2020. At the day’s high, the stock was up 233% during Tuesday’s trade.
Soon after the surge, the late-stage biopharmaceuticals company announced a $150 million share sale via JPMorgan and TD Cowen. The stock plunged 12% in extended trading after the share sale announcement.
Aside from the share sale, analysts said the results add to growing evidence of the potential for cancer vaccines, particularly after an earlier attempt by Moderna Inc. and Merck & Co. for a shot that targeted Melanoma.
“The positive findings for Sellas’ vaccine, also known as GPS, could usher in a new treatment option for patients,” Alliance Global Partners analyst James Molloy said. “This represents blockbuster data for a difficult indication and, if approved, could lead to GPS becoming the standard of care,” Molloy wrote in a note to clients.
According to data from S3 Partners, short interest in the stock rose to 29% of Sellas’ free float after Tuesday’s surge, a sign of bearish bets against the company.
The off-the-shelf vaccine consists of synthetic peptides that stimulate an immune response against WT1, a protein found in the vast majority of acute myeloid leukaemia cases, according to a statement from Memorial Sloan Kettering Cancer Centre. Researchers at Memorial Sloan Kettering Cancer Centre developed the vaccine, which the centre licensed to Sella in 2014.
(With Inputs From Agencies.)
Read more: A series of bizarre incidents are redefining corporate risk
